Parkinson's disease and deep brain stimulation of the subthalamic nucleus (STN-DBS): long-term disease evaluation and neuropsychological outcomes in a 9-year matched-controlled study.

Matched-controlled long-term disease evaluation and neuropsychological outcomes derived from deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson´s disease (PD) are lacking, with inconsistent results regarding the cognitive impact of this procedure. Here we study the long-term effects associated to DBS comparing outcomes with a matched control group. A prospective observational study of 40 patients with PD with bilateral STN-DBS, with a mean follow-up of 9 (6-12) years was conducted. Disease evaluation was performed using the UPDRS-III, UPDRS-II, Hoehn-Yahr, and Schwab-England scales. Neuropsychological assessments were achieved utilizing the MMSE, DRS, RAVLT, BVRT, Stroop, and verbal fluency tests. A control group was used for comparison. Statistical analysis was performed with SPSSv.26. 40 patients were included, with a mean age of 62.8 ± 8.5 at the time of intervention. An improvement in motor symptoms of 48.6% (p < 0.001) and a reduction in LED of 58.6% (p < 0.001) was observed. No significant differences were observed in the MMSE (p = 0.414), DRS (p = 0.251), memory or interference assessments. A worsening in the construction subscale of DRS (p < 0.05) and in verbal fluency (phonemic and semantic) (p < 0.05) was observed. A head-to-head comparison showed significant differences between groups. An age ≤ 60 years was associated with a good long-term clinical prognosis (p = 0.019;OR = 6.75). STN-DBS is an effective and safe therapeutic option for the control of motor symptoms. However, it is associated with a selective deterioration in some cognitive functions in the long term. This study comprehensively evaluates STN-DBS in Parkinson´s disease in the long term, with findings that should be considered when indicating surgery in PD patients.

Cabrera-Montes J ，Sanz-Arranz A ，Hernandez-Vicente J ，Lara-Almunia M ... -  《-》

Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.

Liu Y ，Li W ，Tan C ，Liu X ，Wang X ，Gui Y ，Qin L ，Deng F ，Hu C ，Chen L ... -  《-》

The effects of bilateral subthalamic nucleus deep brain stimulation (STN DBS) on cognition in Parkinson disease.

Heo JH ，Lee KM ，Paek SH ，Kim MJ ，Lee JY ，Kim JY ，Cho SY ，Lim YH ，Kim MR ，Jeong SY ，Jeon BS ... -  《JOURNAL OF THE NEUROLOGICAL SCIENCES》

Field H1 of Forel vs Subthalamic Nucleus Electrical Stimulation in Parkinson's Disease: Long-term Effects on Motor Symptoms and Quality of Life.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) relieves motor symptoms, including levodopa-responsive gait disorders in Parkinson's disease (PD). Traditionally, STN-DBS is not indicated to treat severe, clinically resistant axial symptoms. In this scenario, field H1 of Forel (FF) stimulation (FF-DBS) is likely a feasible option, given it improves motor symptoms, including freezing of gait (FOG), as shown by a short-term study. However, no data are available about the long-term effects of this therapy. Finally, no study has compared the long-term effects of FF and STN-DBS. We report the long-term outcome (>five years) of bilateral FF-DBS in patients with PD. We also compare the effects of FF-DBS and STN-DBS on motor symptoms, cognition, and quality of life. We studied 22 patients (ten with FF-DBS and 12 with STN-DBS). Motor symptoms, cognition, quality of life, and gait symptoms were assessed using the motor part of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS III), the Mattis Dementia Rating Scale, the 39-item PD quality of life (PDQ-39), and the FOG questionnaire (FOG score) respectively. The levodopa equivalent daily dose was recorded. Comparisons of the FF and STN-DBS results were conducted. The mean follow-up was 6.18 years (95% CI: 5.57-6.78). Compared with the preoperative period, patients with FF had an average reduction of 32.2% in the MDS-UPDRS III scores (p < 0.01), a decrease of 35.3% in the FOG scores (p < 0.01), and an improvement of 25.9% in the PDQ-39 (p < 0.01). There was a 7.5% decrease in cognition (p < 0.01). Levodopa equivalent dose (LED) was reduced by 26.3% (p < 0.01). The STN group had an average reduction of 39.4% in the MDS-UPDRS III scores (p < 0.01), a decrease of 23.7% in the FOG scores (p < 0.01), and an improvement of 33.2% in the PDQ-39 scores (p < 0.01). Cognition decreased by 1.6% (p < 0.01) and LED by 15.06% (p = 0.02). Patients with FF-DBS were older than those with STN-DBS at the time of surgery: 61.2 years and 55.7 years, respectively (p = 0.02), and had longer duration of disease (p = 0.02). Patients with FF-DBS had a greater reduction in FOG (p = 0.02) than did the STN group and presented with a greater decrease in cognition (p < 0.01) after five years. STN-DBS had a greater effect on quality of life. Both FF-DBS and STN-DBS relieved motor symptoms and improved quality of life over a long-term period. Patients with FF-DBS had a higher reduction in both FOG and in LED than did those with STN-DBS. These data support our hypothesis that FF-DBS is a safe and efficient option for treating motor symptoms in PD, including FOG in advanced stages.

Rodrigues JPA ，Rocha MSG ，Laube KAC ，Iglesio R ，Filho PRT ，Freitas JL ，Figueiredo EG ，Carlotti CG Jr ，Soriano DC ，Godinho F ... -  《-》

Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease.

Subthalamic (STN) and pallidal (GPi) deep brain stimulation (DBS) improve quality of life, motor, and nonmotor symptoms (NMS) in advanced Parkinson's disease (PD). However, few studies have compared their nonmotor effects. To compare nonmotor effects of STN-DBS and GPi-DBS. In this prospective, observational, multicenter study including 60 PD patients undergoing bilateral STN-DBS (n = 40) or GPi-DBS (n = 20), we examined PDQuestionnaire (PDQ), NMSScale (NMSS), Unified PD Rating Scale-activities of daily living, -motor impairment, -complications (UPDRS-II, -III, -IV), Hoehn&Yahr, Schwab&England Scale, and levodopa-equivalent daily dose (LEDD) preoperatively and at 6-month follow-up. Intra-group changes at follow-up were analyzed with Wilcoxon signed-rank or paired t-test, if parametric tests were applicable, and corrected for multiple comparisons. Inter-group differences were explored with Mann-Whitney-U/unpaired t-tests. Analyses were performed before and after propensity score matching which balanced out demographic and preoperative clinical characteristics. Strength of clinical changes was assessed with effect size. In both groups, PDQ, UPDRS-II, -IV, Schwab&England Scale, and NMSS improved significantly at follow-up. STN-DBS was significantly better for LEDD reduction, GPi-DBS for UPDRS-IV. While NMSS total score outcomes were similar, explorative NMSS domain analyses revealed distinct profiles: Both targets improved sleep/fatigue and mood/cognition, but only STN-DBS the miscellaneous (pain/olfaction) and attention/memory and only GPi-DBS cardiovascular and sexual function domains. To our knowledge, this is the first study to report distinct patterns of beneficial nonmotor effects of STN-DBS and GPi-DBS in PD. This study highlights the importance of NMS assessments to tailor DBS target choices to patients' individual motor and nonmotor profiles.

Dafsari HS ，Dos Santos Ghilardi MG ，Visser-Vandewalle V ，Rizos A ，Ashkan K ，Silverdale M ，Evans J ，Martinez RCR ，Cury RG ，Jost ST ，Barbe MT ，Fink GR ，Antonini A ，Ray-Chaudhuri K ，Martinez-Martin P ，Fonoff ET ，Timmermann L ，EUROPAR and the IPMDS Non Motor PD Study Group ... -  《-》